Who Owns GoodRx Company?

GoodRx Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns GoodRx?

Understanding the ownership of a digital healthcare platform like GoodRx is key to grasping its strategic direction and accountability. The company's IPO in September 2020 marked a significant shift in its ownership structure.

Founded in 2011, GoodRx aimed to bring transparency to prescription drug pricing in the U.S. The platform now offers services beyond price comparison, including telehealth, and in 2024, it served nearly 30 million consumers, facilitating approximately $17 billion in savings.

Who owns GoodRx? This question leads us to examine the stakes held by its founders, major investors, and public shareholders, revealing insights into its financial health and strategic priorities.

GoodRx was established in 2011 in Santa Monica, California, by its three founders: Trevor Bezdek, Doug Hirsch, and Scott Marlette. These individuals brought diverse expertise to the venture, aiming to bring transparency to prescription drug pricing. Their collective vision was to create a platform that allowed users to compare prices and access discounts for medications.

Founding Team Expertise

Doug Hirsch leveraged his product development experience from tech giants like Facebook and Yahoo to enhance user experience. Trevor Bezdek, an experienced entrepreneur, guided the business strategy. Scott Marlette, with a background in engineering from Facebook and Google, was instrumental in building the company's technological infrastructure.

Founders' Vision

The core mission of the founders was to tackle the opacity in prescription drug pricing. They envisioned a user-friendly platform that would empower consumers by providing accessible price comparisons and discount opportunities.

Initial Equity Structure

While the precise initial equity distribution among the founders is not publicly disclosed, it is typical for founders to hold substantial ownership stakes. These stakes are often subject to vesting schedules to ensure long-term commitment to the company's success.

Early Funding Sources

Initial capital for GoodRx was derived from the founders' personal investments and contributions from angel investors. This early backing was crucial for the company's inception and growth.

Key Early Investors

Venture capital firms played a significant role in the company's early stages. Lerer Hippeau was among the first institutional investors, making its initial investment in GoodRx's Series A funding round in November 2011. Other notable early institutional backers included Upfront Ventures, Highland Capital Partners, and SV Angel.

Impact of Early Investments

These early investment agreements and financial backing were foundational in establishing the company's initial ownership structure. They also underscored the founding team's dedication to their mission and the potential they saw in the market.

The founders' commitment and the early support from investors laid the groundwork for GoodRx's subsequent growth and its position in the market, which has been analyzed in the Competitors Landscape of GoodRx.

Founders and Early Ownership Overview

GoodRx was founded in 2011 by Trevor Bezdek, Doug Hirsch, and Scott Marlette, who aimed to bring transparency to prescription drug pricing. Their combined expertise in product development, business strategy, and engineering was pivotal in establishing the company. Early funding came from the founders themselves and angel investors, with significant contributions from venture capital firms like Lerer Hippeau, Upfront Ventures, Highland Capital Partners, and SV Angel, shaping the initial ownership structure and reflecting the founders' dedication.

• Founders: Trevor Bezdek, Doug Hirsch, Scott Marlette
• Founding Year: 2011
• Initial Focus: Prescription drug price transparency and discounts
• Key Early Investors: Lerer Hippeau, Upfront Ventures, Highland Capital Partners, SV Angel
• Founders' Roles: Product development, business strategy, technology development

GoodRx SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership of GoodRx has seen significant shifts, particularly following its Initial Public Offering (IPO) in September 2020. This event marked a major transition, with the company raising $1.1 billion at $33.00 per share and commencing trading on NASDAQ under the ticker 'GDRX'. Initially, the market capitalization stood at approximately $12.7 billion.

Institutional investors now hold a substantial portion of GoodRx stock, accounting for 63.47% as of July 9, 2025. While specific holdings fluctuate and are detailed in quarterly SEC filings, private equity firms like Silver Lake Partners, Francisco Partners, and Spectrum Equity have historically been key stakeholders. Silver Lake Partners, for example, invested $125 million in a private placement during the IPO, intending to secure a one-third stake post-offering. The company's co-founders, Doug Hirsch and Trevor Bezdek, continue to hold individual stakes, though their ownership percentages have been diluted over time.

Understanding GoodRx's Share Structure

GoodRx operates with a dual-class stock system, influencing voting power and control.

• Class A common stock: Each share carries one vote.
• Class B common stock: Each share carries ten votes.
• As of April 8, 2024, Class B shareholders controlled approximately 96.8% of the total voting power.
• This structure grants significant influence to Class B stockholders on corporate decisions.
• Understanding this structure is key to grasping who controls GoodRx stock and voting rights.

The dual-class stock structure, comprising Class A and Class B common stock, significantly shapes the ownership and control dynamics of GoodRx. Holders of Class A shares are entitled to one vote per share, while Class B shareholders possess ten votes per share. This disparity means that as of April 8, 2024, Class B common stock represented approximately 96.8% of the total voting power, granting its holders substantial influence over critical corporate matters, including the election of directors and approval of major transactions. This structure is a crucial element in understanding the overall GoodRx ownership structure and how decisions are made within the GoodRx company owner framework. For insights into how the company has navigated its growth, explore the Growth Strategy of GoodRx.

GoodRx PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of early 2025, GoodRx's Board of Directors includes its co-founders, key management, and representatives from significant investors, ensuring a blend of operational insight and strategic oversight. The board composition reflects the company's journey from its founding to its current public status.

GoodRx employs a dual-class share structure, where Class A shares carry one vote and Class B shares carry ten votes. This structure significantly concentrates voting power with holders of Class B stock, typically comprising management and early investors. Amendments to key provisions concerning these share classes require approval from at least 66 2/3% of the outstanding Class B common stock, voting as a separate class. This arrangement ensures that those with a long-term stake and deep involvement in the company retain substantial control over major decisions, while the presence of institutional investors still promotes accountability to the broader shareholder base.

Understanding Voting Power at GoodRx

The ownership structure at GoodRx is heavily influenced by its dual-class share system. This means that not all shares are created equal when it comes to voting rights.

• Class A shareholders have one vote per share.
• Class B shareholders have ten votes per share.
• Holders of Class B stock, primarily management and early investors, wield significant control.
• Amendments to share class provisions need a 66 2/3% approval from Class B shareholders.
• This structure impacts who ultimately controls GoodRx stock and voting rights.

GoodRx Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

In recent years, GoodRx has seen significant shifts in its leadership and ownership landscape. Co-founders Trevor Bezdek and Doug Hirsch transitioned from co-CEO roles in April 2023, with Scott Wagner stepping in as interim CEO until January 2025. Wendy Barnes assumed the President and CEO positions on January 1, 2025, followed by Christopher McGinnis's appointment as CFO in February 2025. These changes indicate a strategic move towards new executive leadership, with founders now focusing on board responsibilities.

The company's market capitalization has experienced a substantial decline since its initial public offering. From a peak of approximately $12.7 billion in September 2020, its market cap was $1.72 billion as of August 1, 2025, marking an 86.44% decrease. Despite this, institutional ownership remains strong at 63.47% as of July 9, 2025, suggesting continued investor confidence. Strategic initiatives, including a partnership with CVS Caremark in July 2023 and the addition of Publix to its GoodRx Gold network in April 2024, alongside an expansion into the over-the-counter market in October 2024, highlight the company's efforts to broaden its service offerings and partnerships within the evolving healthcare sector. These developments are crucial for understanding the Revenue Streams & Business Model of GoodRx.

Market Capitalization Trend

GoodRx's market capitalization fell from $12.7 billion at its IPO to $1.72 billion by August 1, 2025. This represents an 86.44% decrease.

Institutional Ownership

As of July 9, 2025, institutional investors held 63.47% of the company's stock. This indicates sustained interest from major financial entities.

Key Strategic Partnerships

Partnerships with CVS Caremark (July 2023) and the inclusion of Publix for GoodRx Gold members (April 2024) aim to enhance user benefits and network reach.

New Market Entry

The company launched an eCommerce service for over-the-counter products in October 2024. This move expands its platform into a new retail segment.

GoodRx Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔